Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $810 Million
- Q3 2024
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 8,020,136 shares of DYN stock, worth $241 Million. This represents 35.54% of its overall portfolio holdings.
Number of Shares
8,020,136
Previous 8,020,136
-0.0%
Holding current value
$241 Million
Previous $283 Million
1.79%
% of portfolio
35.54%
Previous 37.7%
Shares
4 transactions
Others Institutions Holding DYN
# of Institutions
210Shares Held
102MCall Options Held
234KPut Options Held
238K-
Black Rock Inc. New York, NY7.39MShares$222 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$206 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$204 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$204 Million0.13% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$191 Million3.2% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.55B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...